Form 8-K - Current report:
SEC Accession No. 0001193125-25-037619
Filing Date
2025-02-27
Accepted
2025-02-27 07:38:51
Documents
16
Period of Report
2025-02-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d928575d8k.htm   iXBRL 8-K 27911
2 EX-99.1 d928575dex991.htm EX-99.1 8918
6 GRAPHIC g928575g0226090125290.jpg GRAPHIC 2680
7 GRAPHIC g928575g0226090125530.jpg GRAPHIC 3652
  Complete submission text file 0001193125-25-037619.txt   172610

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA zvra-20250226.xsd EX-101.SCH 2842
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE zvra-20250226_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zvra-20250226_pre.xml EX-101.PRE 11256
18 EXTRACTED XBRL INSTANCE DOCUMENT d928575d8k_htm.xml XML 3650
Mailing Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747
Business Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 (321) 939-3416
ZEVRA THERAPEUTICS, INC. (Filer) CIK: 0001434647 (see all company filings)

EIN.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36913 | Film No.: 25673059
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)